Company profile: AltruBio
1.1 - Company Overview
Company description
- Provider of targeted antibody therapeutics for cancer and immune related inflammatory diseases, including ALTB-168, a humanized antibody targeting late-stage, chronically activated T cells with clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease, and ALTB-268, a second-generation antibody in trials for ulcerative colitis and psoriatic arthritis.
Products and services
- Targeted Antibody Therapeutics Development: Develops targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases, concentrating on disease-specific applications
- ALTB-168: Humanized therapeutic antibody targeting late-stage, chronically activated T cells, demonstrating clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease
- ALTB-268: Second-generation antibody engineered to improve potency in down-regulating chronic pathogenic T cells, currently in clinical trials for ulcerative colitis and psoriatic arthritis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AltruBio
Advanced Accelerator Applications
HQ: France
Website
- Description: Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Accelerator Applications company profile →
Everest Medicines
HQ: United States
Website
- Description: Provider of novel pharmaceutical therapies, including VELSIPITY (etrasimod), an oral once-daily S1P modulator for moderately to severely active ulcerative colitis; Nefecon, an oral delayed-release budesonide for primary IgA nephropathy in adults; Xerava (eravacycline), an IV antibiotic for complicated intra-abdominal infections; Zetomipzomib for autoimmune diseases; EVER001 for renal diseases; and an mRNA platform for vaccines and therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Everest Medicines company profile →
NanoSmart Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform drug delivery technologies for solid-tumor cancers, including a human-derived Anti-Nuclear Antibody targeting necrotic tumor tissue, ANA-conjugated lipid nanoparticles for direct API delivery to tumor sites, and a thermally sensitive nanoemulsion enabling stable storage and release at body temperature, plus licensing and partnerships to enhance existing cancer drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoSmart Pharmaceuticals company profile →
Monte Rosa Therapeutics
HQ: Switzerland
Website
- Description: Provider of platforms and tools for protein degradation therapeutics, including the QuEEN Platform, the AI-driven Degron Encyclopedia, a proprietary molecular glue degrader (MGD) library, and the Glueomics Toolbox; advancing a pipeline of MGDs for cancer, autoimmune, and inflammatory diseases, with an expanded access policy for investigational drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Monte Rosa Therapeutics company profile →
Qualigen Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology, operating as a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qualigen Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AltruBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AltruBio
2.2 - Growth funds investing in similar companies to AltruBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AltruBio
4.2 - Public trading comparable groups for AltruBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →